Translate this page into:
Statin Therapy in Indian Women with Dyslipidemia: Myths, Evidence, Adherence, and the Role of Nutrition, Nutraceuticals, Yoga, Stress Management, and Mental Health in Lipid Control
*Corresponding author: Pathapati Rama Mohan, Department of Pharmacology, Narayana Medical College, Nellore, Andhra Pradesh, India. ramamohanpathapati@gmail.com
-
Received: ,
Accepted: ,
How to cite this article: Nousheen S, Bhakthavastala Reddy C , Madhavi LV, Mohan PR, Navuluri M. Statin Therapy in Indian Women with Dyslipidemia: Myths, Evidence, Adherence, and the Role of Nutrition, Nutraceuticals, Yoga, Stress Management, and Mental Health in Lipid Control. Indian J Cardiovasc Dis Women. 2025;10:304-11. doi: 10.25259/IJCDW_53_2025
Abstract
Dyslipidemia has become one of the most common metabolic abnormalities among Indian women and a major contributor to the growing burden of cardiovascular disease. Although statins are well established as effective lipid-lowering drugs, their use in Indian women remains inconsistent and delayed. Meta-analyses show a 22–30% reduction in major cardiovascular events among women adherent to statin therapy. Myths about infertility, hepatic damage, muscle weakness, and bone loss, together with sociocultural and economic barriers, have limited their acceptance. This narrative review summarizes evidence from 2010 to 2025 drawn from randomized trials, meta-analyses, registry data, and Indian observational studies. It highlights gender-specific differences in lipid patterns, efficacy, tolerability, and adherence and integrates pharmacological and lifestyle approaches relevant to Indian practice. Combining statin therapy with improved diet, selected nutraceuticals, yoga, and psychosocial counselling can enhance adherence and outcomes. Strengthening gender-aware prescribing and culturally compatible education can help close the treatment gap between Indian and global populations.
Keywords
Adherence
Dyslipidemia
Indian women
Lifestyle modification
Menopause
Nutraceuticals
Statins
Yoga
INTRODUCTION
Cardiovascular disease is now the leading cause of death among women in India, surpassing maternal and infectious causes.[1] The ICMR-INDIAB study showed that more than 70% of Indian adults have at least one lipid abnormality, and women are especially prone to low high-density lipoprotein-cholesterol (HDL-C) and high triglycerides (TGs).[2] Despite this, the diagnosis and treatment of dyslipidemia in women are often delayed, and adherence to statins remains poor.[2,3] In clinical practice, several beliefs persist that statins cause infertility, damage the liver, or produce chronic fatigue. These misconceptions, combined with limited access to lipid testing and out-of-pocket expenditure, lead to major gaps in cardiovascular prevention.[4] Landmark clinical trials such as 4S,[5] Heart Protection Study (HPS),[6] and justification for the use of statins in prevention: An intervention trial evaluating rosuvastatin (JUPITER)[7] has clearly demonstrated that women benefit from statin therapy to the same extent as men when adherence is maintained. However, sex differences in pharmacokinetics and body composition may influence tolerability.[8,9] In India, additional challenges such as early menopause, diets rich in refined carbohydrates, and low omega-3 intake worsen the atherogenic profile.[10-17] On the positive side, traditional practices such as yoga, meditation, and pranayama – supported by the Ministry of AYUSH – have shown improvement in lipid and stress parameters.[16-18] This review was therefore undertaken to consolidate evidence on the efficacy, safety, and adherence of statins among Indian women and to present practical recommendations for integrating lifestyle measures into routine lipid management.
MATERIALS AND METHODS
This article follows a narrative-review design with systematic search principles. Electronic databases – PubMed, Scopus, Embase, and Google Scholar – were searched for studies published between 2010 and 2025 using the keywords statin, women, India, yoga, and nutraceutical. Only English-language human studies were included. Randomized controlled trials, cohort studies, registry analyses, and systematic reviews were considered relevant, while animal studies and grey literature were excluded. Two reviewers independently screened the search results for eligibility. Differences were resolved by consensus. A formal risk-of-bias assessment was not performed because the objective was to summarize available clinical and observational evidence rather than conduct a meta-analysis [Figure 1]. Data from international studies were used for comparison whenever Indian evidence was limited. The synthesis focuses on areas of clinical importance:
- Preferred Reporting Items for Systematic Reviews and Meta-analyses diagram.
Efficacy of statins in women,
Common myths and misconceptions,
Adherence barriers specific to India,
Life-stage and hormonal considerations,
Role of nutrition, nutraceuticals, and yoga, and
Practical recommendations for Indian clinicians.
RESULTS
Statin efficacy and myths
Landmark randomized controlled trials such as 4S,[5] HPS,[6] and JUPITER[7] have established that statins lower major cardiovascular events by 25–35% in both sexes. Sub-analyses confirmed that when adherence is maintained, women obtain the same cardiovascular protection as men. However, Indian registry data (LIPID-LAD and PURE-India) show that fewer than one-third of eligible women are prescribed statins, and only 15–20% achieve the target low-density lipoprotein cholesterol (LDL-C) <70 mg/dL.[19,20]
Common fears of infertility, liver injury, or muscle pain remain strong barriers.
Adherence challenges specific to Indian women
Adherence is influenced by cost, caregiving priorities, low risk perception, and psychosocial stress.[2,3] Women frequently stop therapy after minor adverse effects or during family health crises [Table 1]. Indian pilot studies demonstrate that pharmacist counseling, family education, and tele-follow-ups improve persistence.[21,22] Table 2 shows the typical dyslipidaemia patterns seen in diabetes, metabolic syndrome, and pregnancy.
| Barrier (common in India) | Impact on therapy | Practical strategy |
|---|---|---|
| Perceived side-effects (SAMS, “liver damage”)[53] | Early discontinuation | Educate; rechallenge; switch to hydrophilic statin; consider alternate-day dosing |
| Out-of-pocket costs | Skipped refills, dose stretching | Use generics; state schemes; FDCs where rational |
| Caregiving burden[31-33] | Missed doses, poor follow-up | Family-based counselling; phone reminders/tele-follow-up |
| Low risk awareness[4] | Late initiation, low intensity | Simple visuals; document LDL targets on prescription |
| Depression/anxiety[34] | Non-adherence | Screen briefly (PHQ-2); refer for counselling; integrate yoga and stress management |
LDL-C: Low-density lipoprotein, SAMS: Statin-associated muscle symptoms, FDC: Fixed-dose combinations, PHQ: Patient health questionnaire, LDL: Low density lipoprotein
| Group | Typical lipid pattern | Key points for Indian practice |
|---|---|---|
| Type 2 diabetes | ↑ TG, ↓ HDL-C, small dense LDL[37-39] | Statins first-line; address glycaemia; consider EPA ethyl for very high TG[47] |
| Metabolic syndrome | ↑ TG, ↑ apoB[42,43] | Intensive lifestyle+statin; recheck LDL-C at 6–12 weeks |
| Pregnancy (gestational dyslipidaemia) | ↑ TG, ↑ VLDL[40] | Avoid statins; consider bile-acid sequestrants/omega-3s; restart post-partum |
LDL-C: Low-density lipoprotein cholesterol, HDL-C: High-density lipoprotein-cholesterol, TG: Triglycerides, HDL-High-Density Lipoprotein Cholesterol, VLDL: Very Low-Density Lipoprotein Cholesterol, EPA: Eicosapentaenoic Acid, apoB: Apolipoprotein B, TC; Total cholesterol
Indian women with diabetes or metabolic syndrome commonly present with high TGs, low HDL-C, and small dense LDL. Statins reduce cardiovascular events by 25– 35% in these groups.[23-25] During pregnancy, statins are contraindicated; bile-acid sequestrants or omega-3 fatty acids are safer.[26] Although statins marginally increase incident of diabetes, the absolute risk is outweighed by the cardiovascular benefit.[27]
Nutrition and nutraceuticals
Dietary patterns in India are high in refined carbohydrates and low in omega-3 fatty acids.[28,29] High-fiber diets and nutraceuticals such as red-yeast rice, plant sterols, and curcumin lower LDL-C by 8–25%. However, quality variation and poor standardization limit their reliability; they are best used as adjuncts [Table 3].
| Intervention | Typical lipid effect | Notes |
|---|---|---|
| High-fibre diet[42,43] | ↓ LDL-C 5–10% | Indian diets are fibre-poor; promote millets and pulses |
| Omega-3 fatty acids[47,48] | ↓ TG 20–30% (variable LDL) | Outcome evidence mixed; prefer EPA ethyl in high TG |
| Red yeast rice[29,30] | ↓ LDL-C 10–25% | Use standardised formulations; monitor for SAMS |
| Plant sterols[32,33] | ↓ LDL-C 8–12% | Add to balanced diet; not a statin substitute |
| Curcumin[31] | ↓ TC/TG; ↑ HDL (modest) | Bioavailability varies; consider enhanced forms |
LDL-C: Low-density lipoprotein cholesterol, HDL-C: High-density lipoprotein-cholesterol, TG: Triglycerides, EPA: Eicosapentaenoic acid, SAMS: Statin-associated muscle symptoms
Yoga and mental-health integration
Studies supported by AYUSH and ICMR demonstrate that structured yoga programs significantly reduce total cholesterol and TGs while improving HDL-C.
Yoga combined with brief counseling enhances medication adherence and psychological well-being [Table 4].[30-32]
| Modality | Lipid and CVD effects | Added value in India |
|---|---|---|
| Structured yoga asanas[49-52] | ↓ TC/LDL/TG; ↑ HDL | High acceptance, low cost |
| Pranayama and mindfulness[49-51] | ↓ stress, modest lipid benefit | Improves sleep and mental focus |
| Yoga+brief counselling[53] | Better persistence with statins | Feasible in community clinics |
LDL: Low-density lipoprotein, HDL: High-density lipoprotein, TG: Triglycerides
Chronic kidney disease (CKD) and familial hypercholesterolemia (FH)
CKD is common in Indian women due to diabetes and hypertension. The SHARP trial[33] demonstrated that simvastatin + ezetimibe reduced major atherosclerotic events without renal harm. Statins remain essential for secondary prevention in CKD,[34] with dose adjustments in advanced stages.[35] FH remains under-recognized; women are diagnosed later and treated less aggressively [Tables 5 and 6].[36,37]
| Evidence | Key findings | Practice notes |
|---|---|---|
| SHARP RCT[23] | ↓ major atherosclerotic events | Combine with ezetimibe; no renal harm |
| Reviews[54-56] | Safe across CKD stages | Adjust dose in advanced CKD; monitor SAMS |
| Indian context[24] | Late diagnosis, undertreatment | Prioritise women with DM/HTN; check eGFR baseline |
eGFR: Estimated glomerular filtration rate, SHARP: Study of heart and renal protection, CKD: Chronic kidney disease, SAMS: Statin-associated muscle symptoms
| Evidence | Key findings | Practice notes |
|---|---|---|
| Long-term cohort[25] | Statins↓ CHD risk≈76% | Cascade screening; start high-intensity early |
| HoFH registry[26] | Sex differences in outcomes | Escalate to ezetimibe/PCSK9 when targets unmet |
CHD: Coronary heart disease, PCSK9: Proprotein convertase subtilisin/Kexin Type 9, HoFH: Homozygous familial hypercholesteremia
Hormonal influence and pharmacokinetic considerations
Postmenopausal women experience higher LDL-C and TG and lower HDL-C.[38] Hydrophilic statins (rosuvastatin and pravastatin) are preferred because women show higher plasma exposure to lipophilic statins [Tables 7 and 8].[39]
| Stage | Lipid change | Clinical implication |
|---|---|---|
| Premenopause[14] | ↑ HDL-C, ↓ LDL-C | Relative protection |
| Menopause transition[60] | ↑ LDL-C, TG, Lp (a) | Accelerated ASCVD risk |
| Premature/surgical menopause[61,62] | ↑ CVD risk 25–87% | Start earlier risk assessment; lower targets |
| MHT use[65] | Improves lipids but↑ VTE risk | Statins remain first-line |
LDL-C: Low-density lipoprotein cholesterol, HDL-C: High-density lipoprotein-cholesterol, CVD: Cardiovascular disease, ASCVD: Atherosclerotic cardio vascular disease, VTE: Venous thromboembolism, MHT: Menopausal hormone therapy, LP(a): Lipoprotein(a)
| Feature | Women | Men | Practical tip |
|---|---|---|---|
| PK exposure[63,64] | Higher at same dose | Lower | Prefer hydrophilic agents if intolerance |
| ADRs[53,65] | More SAMS/fatigue | Fewer | Start-low, go-slow; alternate-day option |
| Prescribing intensity[3,4] | Less high-intensity | More | Correct undertreatment; document targets |
| Life-stage factors[11-15] | PCOS, pregnancy, menopause | — | Stop statins in pregnancy; advise contraception |
SAMS: Statin-associated muscle symptoms,
LDL-C targets for Indian practice
Guidelines recommend aggressive LDL-C reduction[40] [Table 9]:
| Risk category | Typical Indian examples | Target LDL-C (mg/dL) | Treatment goal |
|---|---|---|---|
| Very-high risk | ASCVD, DM with organ damage, CKD≥3, FH | <55 and ≥50% ↓ from baseline | High-intensity statin±ezetimibe/PCSK9 |
| High risk | Multiple risk factors or DM without damage | <70 | Moderate-to high-intensity statin |
| Moderate risk | 1–2 risk factors (family history, sedentary) | <100 | Lifestyle±moderate intensity statin |
| Low risk | Healthy premenopausal women | <115 | Lifestyle; periodic review |
| Special situations | Pregnancy planning, CKD, PCOS, premature menopause | Individualised | Avoid statins in pregnancy; resume later |
LDL-C: Low-density lipoprotein cholesterol, CKD: Chronic kidney disease, PCSK9: Proprotein Convertase Subtilisin/Kexin Type 9, FH: Familial hypercholesterolaemia
Very high risk <55 mg/dL and ≥50% reduction from baseline
High risk <70 mg/dL
Moderate risk <100 mg/dL
Low risk <115 mg/dL.
Special populations such as pregnancy, CKD, polycystic ovary syndrome, and premature menopause require individualized plans.
DISCUSSION
The dyslipidemia profile of Indian women differs markedly from that of Western women, both in biochemical pattern and sociocultural determinants. Low HDL-C and high TG predominate, influenced by early menopause, carbohydrate-rich diet, and low physical activity.[41,42] Despite compelling global evidence, Indian women continue to be underdiagnosed and undertreated.[43] This gap is fueled by myths, financial limitations, and inadequate risk communication. Statins remain the most effective lipid-lowering drugs.
Hydrophilic statins should be preferred in women with prior intolerance, and alternate-day dosing may minimize myalgia.[44] Patient education must emphasize that mild symptoms are manageable. Recording LDL-C targets on prescriptions helps focus attention on measurable goals.[45] Integrating lifestyle modification enhances adherence. Yoga and meditation, being inexpensive and culturally acceptable, complement pharmacological therapy.[46-49] Family involvement and pharmacist-supported follow-up sustain long-term compliance.[50,51] Nutraceuticals can provide moderate additional LDL-C lowering but must be standardized and monitored.[52-57] The global PURE study[58] highlights that South-Asian women have the lowest continuation rate for statins worldwide. Hence, India needs structured lipid-screening programs beginning at 30–35 years, nurse-led counseling, and community-based education.[59] Gender-aware cardiovascular prevention policies should be prioritized in national health missions.[60] Newer agents such as ezetimibe and PCSK9 inhibitors[61-63] provide further LDL-C reduction but are expensive. Local production and inclusion under public-health schemes could make them accessible. Until then, optimal use of statins with culturally tailored lifestyle support remains the most practical solution. Future research must focus on generating sex-disaggregated Indian registry data to understand prescription patterns and outcomes. Cost-effective models integrating yoga, diet, and adherence counselling at the primary-care level can bridge the gap between evidence and practice.[66-74]
Limitations
This review summarizes the best available evidence from 2010 to 2025; however, certain limitations must be acknowledged. First, it is a narrative synthesis and not a meta-analysis; hence, quantitative comparisons were not performed. Second, many Indian studies are observational or registry-based, with small sample sizes and heterogeneous methodology. Third, sex-specific data are often missing from national registries, making it difficult to calculate precise prevalence and adherence rates for women. Fourth, information on the long-term safety of nutraceuticals and yoga interventions remains limited, as most trials were of short duration and variable quality. Despite these gaps, the synthesis provides a comprehensive overview of current Indian and global evidence and identifies priority areas for research and policy development.
CONCLUSION
Dyslipidemia among Indian women represents a major, yet under-recognized, contributor to cardiovascular morbidity and mortality. Although statins remain the cornerstone of therapy, their optimal use is restricted by myths, affordability issues, and limited awareness.
Evidence clearly demonstrates that when adherence is maintained, women derive equal benefit to men in reducing cardiovascular risk. Hydrophilic statins, low-dose initiation, and alternate-day regimens can improve tolerability. Integrating lifestyle modification – including improved diet, structured yoga practice, and psychosocial counselling – is crucial for long-term adherence. Culturally sensitive patient education, family participation, and pharmacist- or nurse-led follow-ups can substantially enhance outcomes. Nutraceuticals may serve as useful adjuncts, provided they are standardized and monitored. To close the gap between global evidence and Indian reality, national health programs should include gender-specific lipid-screening policies, affordable access to statins, and community-based education. Building a strong Indian database with sex-disaggregated registry data on prescribing and adherence patterns will help shape future clinical guidelines.
Until novel lipid-lowering agents become economically viable, the focus should remain on optimizing statin therapy and sustaining adherence through culturally compatible approaches.
Ethical approval:
Institutional Review Board approval is not required.
Declaration of patient consent:
Patient’s consent is not required as there are no patients in this study.
Conflicts of interest:
There are no conflicts of interest.
Use of artificial intelligence (AI)-assisted technology for manuscript preparation:
The authors confirm that there was no use of artificial intelligence (AI)-assisted technology for assisting in the writing or editing of the manuscript and no images were manipulated using AI.
Financial support and sponsorship: Nil.
References
- Prevalence of CVD Among Indian Adult Population: Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2025;22:539.
- [CrossRef] [PubMed] [Google Scholar]
- EU-Wi de Cross-Section al Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: The DA VINCI Study. Europ J Prevent Cardiol. 2021;28:1279-89.
- [CrossRef] [PubMed] [Google Scholar]
- Gender-Related Factors in Medication Adherence for Metabolic and Cardiovascular Health. Metabolites. 2023;13:1087.
- [CrossRef] [PubMed] [Google Scholar]
- Unique Features of Dyslipidemia in Women Across a Lifetime and a Tailored Approach to Management. Am J Prevent Cardiol. 2024;18:100666.
- [CrossRef] [PubMed] [Google Scholar]
- Scandinavian Simvastatin Survival Study Group: Randomised Trial of Cholesterol Lowering in 4444 Patients with Coronary Heart Disease: The Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;344:1383-9.
- [CrossRef] [Google Scholar]
- MRC/BHF Heart Protection Study of Cholesterol Lowering with Simvastatin in 20,536 High-Risk Individual: A Randomised Placebo-Controlled Trial. Rev Port Cardiol. 2002;21:801-2.
- [Google Scholar]
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med. 2008;359:2195-207.
- [CrossRef] [PubMed] [Google Scholar]
- Sex-Related Differences in Pharmacokinetics and Pharmacodynamics of Frequently Prescribed Drugs: A Review of the Literature. Adv Ther. 2020;37:644-55.
- [CrossRef] [PubMed] [Google Scholar]
- The Influence of Sex on Pharmacokinetics. Clin Pharmacokinet. 2003;42:107-21.
- [CrossRef] [PubMed] [Google Scholar]
- Impact of Diet on Cardiovascular Diseases: Coronary Artery Disease Risk Factors. Asian J Cardiol Res. 2021;5:126-42.
- [Google Scholar]
- Postmenopausal Status and Early Menopause as Independent Risk Factors for Cardiovascular Disease: A Meta-Analysis. Menopause. 2006;13:265-79.
- [CrossRef] [PubMed] [Google Scholar]
- Puerarin 6''-O-Xyloside improves Postmenopausal Lipid Metabolic Disorders via the PPARa-mediated FAO pathway.
- [Google Scholar]
- Menopause Symptom Management in Women with Dyslipidemias: An EMAS Clinical Guide. Maturitas. 2020;135:82-8.
- [CrossRef] [PubMed] [Google Scholar]
- Nutrition Transition in India: Secular Trends in Dietary Intake and their Relationship to Diet-Related NonCommunicable Diseases. J Diabetes. 2011;3:278-92.
- [CrossRef] [PubMed] [Google Scholar]
- Diet and Physical Activity Among Women in Urban and Rural Areas in South India: A Community Based Comparative Survey. J Family Med Prim Care. 2013;2:334-8.
- [CrossRef] [PubMed] [Google Scholar]
- Impact of a Nurse-Led Teleconsultation Strategy for Cardiovascular Disease Management during COVID-19 Pandemic in India: A Pyramid Model Study. BMJ Open. 2022;12:e056408.
- [CrossRef] [PubMed] [Google Scholar]
- The Effectiveness of Yoga in Modifying Risk Factors for Cardiovascular Disease and Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Eur J Prev Cardiol. 2016;23:291-307.
- [CrossRef] [PubMed] [Google Scholar]
- Stress and Cardiovascular Disease. Nat Rev Cardiol. 2012;9:360-70.
- [CrossRef] [PubMed] [Google Scholar]
- Metabolic, Behavioural, and Psychosocial Risk Factors and Cardiovascular Disease in Women Compared with Men in 21 High-Income, Middle-Income, and Low-Income Countries: An Analysis of the Pure Study. Lancet. 2022;400:811-21.
- [CrossRef] [PubMed] [Google Scholar]
- Prevalence of Dyslipidemia in Urban and Rural India: The ICMR-INDIAB Study. PLoS One. 2014;9:e96808.
- [CrossRef] [PubMed] [Google Scholar]
- Patterns and Predictors of Medication Adherence to Lipid-Lowering Therapy in Children Aged 8 to 20 Years. J Clin Lipidol. 2016;10:824-32.e2.
- [CrossRef] [PubMed] [Google Scholar]
- A Metaanalysis of Interventions to Improve Adherence to Lipid-Lowering Medication. Ochsner J. 2016;16:230-7.
- [CrossRef] [Google Scholar]
- Lipids and Lipid Management in Diabetes. Best Pract Res Clin Endocrinol Metab. 2014;28:325-38.
- [CrossRef] [PubMed] [Google Scholar]
- Prevalence of Dyslipidaemia and Factors Associated with Dyslipidaemia among South Asian Adults: The Center for Cardiometabolic Risk Reduction in South Asia Cohort Study. Natl Med J India. 2020;33:137-45.
- [CrossRef] [PubMed] [Google Scholar]
- Lipid Association of India (LAI) Expert Consensus Statement on Management of Dyslipidaemia in Indians 2017: Part 2. Clin Lipidol. 2017;12:56-109.
- [Google Scholar]
- Statins and Higher Diabetes Mellitus Risk: Incidence, Proposed Mechanisms, and Clinical Implications. Cardiol Rev. 2021;29:314-22.
- [CrossRef] [PubMed] [Google Scholar]
- On-Treatment Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, Triglycerides, and Lipid Ratios in Relation to Residual Vascular Risk After Treatment with Potent Statin Therapy: JUPITER (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) J Am Coll Cardiol. 2012;59:1521-8.
- [CrossRef] [PubMed] [Google Scholar]
- Association of Higher Omega-6/Omega-3 Fatty Acids in the Diet with Higher Prevalence of Metabolic Syndrome in North India. MOJ Public Health. 2017;6:193.
- [CrossRef] [Google Scholar]
- Diet Patterns Are Associated with Circulating Metabolites and Lipid Profiles of South Asians in the United States. J Nutr. 2022;152:2358-66.
- [CrossRef] [PubMed] [Google Scholar]
- Effectiveness of Yoga Lifestyle on Lipid Metabolism in a Vulnerable Population-A Community Based Multicenter Randomized Controlled Trial. Medicines (Basel). 2021;8:37.
- [CrossRef] [PubMed] [Google Scholar]
- Diabetic Yoga Protocol Improves Glycemic, Anthropometric and Lipid Levels in High Risk Individuals for Diabetes: A Randomized Controlled Trial from Northern India. Diabetol Metab Syndr. 2021;13:149.
- [CrossRef] [PubMed] [Google Scholar]
- Evidence-Based Ayurveda Interventions for Sustainable Obesity Management: Efficacy, Safety, and Long-Term Outcomes. J Drug Res Ayur Sci. 2025;10:S78-81.
- [CrossRef] [Google Scholar]
- Study of Heart and Renal Protection (SHARP): Randomized Trial to Assess the Effects of Lowering Low-Density Lipoprotein Cholesterol among 9,438 Patients with Chronic Kidney Disease. Am Heart J. 2010;160:785-94.e10.
- [CrossRef] [PubMed] [Google Scholar]
- Statins and Cardiovascular Primary Prevention in CKD: A Meta-Analysis. Clin J Am Soc Nephrol. 2015;10:732-9.
- [CrossRef] [PubMed] [Google Scholar]
- The Role of Statins in Managing Chronic Kidney Disease: A Comprehensive Review. Int J Nutr Pharmacol Neurol Dis. 2025;15:10-7.
- [CrossRef] [Google Scholar]
- Sex Differences in Treatment of Familial Hypercholesterolaemia: A Meta-Analysis. Eur Heart J. 2024;45:3231-50.
- [CrossRef] [PubMed] [Google Scholar]
- Familial Hypercholesterolemia: An Under-Recognized but Significant Concern in Cardiology Practice. Clin Cardiol. 2014;37:119-25.
- [CrossRef] [PubMed] [Google Scholar]
- The Influence of Female Sex and Estrogens on Drug Pharmacokinetics: What is the Evidence? Expert Opin Drug Metab Toxicol. 2025;21:637-47.
- [CrossRef] [PubMed] [Google Scholar]
- Hydrophilic or Lipophilic Statins? Front Cardiovasc Med. 2021;8:687585.
- [CrossRef] [PubMed] [Google Scholar]
- Assessing LDL-C Goal Attainment in Secondary Prevention of Atherosclerotic Cardiovascular Disease: Insights from the LAI-LCARE Survey in India. J Clin Lipidol. 2025;19:e64-5.
- [CrossRef] [Google Scholar]
- A Low-Carbohydrate, High-Fat Diet Leads to Unfavorable Changes in Blood Lipid Profiles Compared to Carbohydrate-Rich Diets with Different Glycemic Indices in Recreationally Active Men. Front Nutr. 2024;11:1473747.
- [CrossRef] [PubMed] [Google Scholar]
- Effects of Two Consecutive Mixed Meals High in Palmitic Acid or Stearic Acid on 8-h Postprandial Lipemia and Glycemia in Healthy-Weight and Overweight Men and Postmenopausal Women: A Randomized Controlled Trial. Eur J Nutr. 2021;60:3659-67.
- [CrossRef] [PubMed] [Google Scholar]
- Premature Coronary Artery Disease and Familial Hypercholesterolemia: Need for Early Diagnosis and Cascade Screening in the Indian Population. Cardiol Res Pract. 2012;2012:658526.
- [CrossRef] [PubMed] [Google Scholar]
- Suggested Clinical Approach for the Diagnosis and Management of “Statin Intolerance” with an Emphasis on Muscle-Related Side-Effects. Intern Med J. 2019;49:1081-91.
- [CrossRef] [PubMed] [Google Scholar]
- Use of health information technology (HIT) to improve statin adherence and low-density lipoprotein cholesterol goal attainment in high-risk patients: Proceedings from a workshop. J Clin Lipidol. 2013;7:573-609.
- [CrossRef] [PubMed] [Google Scholar]
- Lifestyle Changes and Meditation: A Synergistic Approach. Multidiscipl Res Area Arts Sci Commerce. 2025;1:6.
- [Google Scholar]
- Integrative Care: Supporting Patients through Complementary and Lifestyle Approaches. In: Transforming Prostate Cancer Care: Advancing Cancer Treatment with Insights from Africa. Berlin: Springer; 2024. p. :233-56.
- [CrossRef] [Google Scholar]
- Integrative Medicine as “Medicine”: A Perspective. New York: Mary Ann Liebert. Inc., Publishers; 2022. p. :86-94.
- [CrossRef] [Google Scholar]
- Integrative Approaches for Health: Biomedical Research, Ayurveda and Yoga. United States: Academic Press; 2015.
- [CrossRef] [Google Scholar]
- Person-Centered Models for Cardiovascular Care: A Review of the Evidence: A Scientific Statement From the American Heart Association. Circulation. 2023;148:512-42.
- [CrossRef] [PubMed] [Google Scholar]
- The Importance of Low-Density Lipoprotein Cholesterol Measurement and Control as Performance Measures: A Joint Clinical Perspective from the National Lipid Association and the American Society for Preventive Cardiology. J Clin Lipidol. 2023;17:208-18.
- [CrossRef] [PubMed] [Google Scholar]
- A Nutraceutical Approach (Armolipid Plus) to Reduce Total and LDL Cholesterol in Individuals with Mild to Moderate Dyslipidemia: Review of the Clinical Evidence. Atheroscler Suppl. 2017;24:1-15.
- [CrossRef] [PubMed] [Google Scholar]
- The Role of Nutraceuticals in Statin Intolerant Patients. J Am Coll Cardiol. 2018;72:96-118.
- [CrossRef] [PubMed] [Google Scholar]
- Lipid-Lowering Nutraceuticals Update on Scientific Evidence. J Cardiovasc Med (Hagerstown). 2020;21:845-59.
- [CrossRef] [PubMed] [Google Scholar]
- Nutraceuticals as an Important Part of Combination Therapy in Dyslipidaemia. Curr Pharm Des. 2017;23:2496-503.
- [CrossRef] [PubMed] [Google Scholar]
- A Systematic Review and Meta-Analysis of Randomized Controlled Trials Investigating the Effects of Curcumin on Blood Lipid Levels. Clin Nutr. 2014;33:406-14.
- [CrossRef] [PubMed] [Google Scholar]
- Effect of Curcumin on Glycaemic and Lipid Parameters in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Reprod Sci. 2022;29:3124-33.
- [CrossRef] [PubMed] [Google Scholar]
- Lessons from PURE on Modifiable Risk. Eur Heart J. 2022;43:2864-6.
- [CrossRef] [PubMed] [Google Scholar]
- Global Cardiovascular Disease Prevention: A Call to Action for Nursing Executive Summary. J Cardiovasc Nurs. 2013;28:505-13.
- [CrossRef] [PubMed] [Google Scholar]
- Community Coalitions' Gender-Aware Policy and Systems Changes to Improve the Health of Women and Girls. Womens Health Issues. 2017;27(Suppl 1):S6-13.
- [CrossRef] [PubMed] [Google Scholar]
- Are PCSK9 Inhibitors the Next Breakthrough in the Cardiovascular Field? J Am Coll Cardiol. 2015;65:2638-51.
- [CrossRef] [PubMed] [Google Scholar]
- Long-Term Efficacy and Safety of Evolocumab in Patients With Hypercholesterolemia. J Am Coll Cardiol. 2019;74:2132-46.
- [CrossRef] [PubMed] [Google Scholar]
- Cholesterol-Lowering Agents: PCSK9 Inhibitors Today and Tomorrow. Circ Res. 2019;124:364-85.
- [CrossRef] [PubMed] [Google Scholar]
- A Cost-Effectiveness Analysis of Over-the-Counter Statins. Am J Manag Care. 2016;22:e294-303.
- [Google Scholar]
- Effect of Gender, Caregiver, on Cholesterol Control and Statin use for Secondary Prevention among Hospitalized Patients with Coronary Heart Disease. Am J Cardiol. 2012;110:1613-8.
- [CrossRef] [PubMed] [Google Scholar]
- Dyslipidemia in Pregnancy: A Systematic Review of Molecular Alterations and Clinical Implications. Biomedicines. 2024;12:2252.
- [CrossRef] [PubMed] [Google Scholar]
- Red Yeast Rice for Dyslipidaemias and Cardiovascular Risk Reduction: A Position Paper of the International Lipid Expert Panel. Pharmacol Res. 2022;183:106370.
- [CrossRef] [PubMed] [Google Scholar]
- The Comparative Efficacy of Plant Sterols and Stanols on Serum Lipids: A Systematic Review and Meta-Analysis. J Am Diet Assoc. 2010;110:719-26.
- [CrossRef] [PubMed] [Google Scholar]
- The Effect of Yoga on the Lipid Profile: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Front Nutr. 2022;9:942702.
- [CrossRef] [PubMed] [Google Scholar]
- Impact of Pranayama and Yoga on Lipid Profile in Normal Healthy Volunteers. J Exerc Physiol Online. 2006;9:1-6.
- [Google Scholar]
- Efficacy of Statins in Familial Hypercholesterolaemia: A Long Term Cohort Study. BMJ. 2008;337
- [CrossRef] [PubMed] [Google Scholar]
- Long-term Efficacy of Lipoprotein Apheresis and Lomitapide in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH): A Cross-National Retrospective Survey. Orphanet J Rare Dis. 2021;16:381.
- [CrossRef] [PubMed] [Google Scholar]
- Sex Differences in Drugs: The Development of a Comprehensive Knowledge Base to Improve Gender Awareness Prescribing. Biol Sex Differ. 2017;8:32.
- [CrossRef] [PubMed] [Google Scholar]
- Study Flow Diagrams in Cochrane Systematic Review Updates: An Adapted PRISMA Flow Diagram. Syst Rev. 2014;3:54.
- [CrossRef] [PubMed] [Google Scholar]